RxDoctor Payments Data

Jillian Sarles, PA

Physician Assistant · Rockwall, TXNPI 1770824567

Payments from drug & device makers

$8,416in general payments, 2019–2025

Across 453 payments — averaging $18.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • Takeda Pharmaceuticals U.S.A., Inc.$890
  • Johnson & Johnson$785
  • Ferring Pharmaceuticals Inc.$487
  • Redhill Biopharma Inc.$401
  • Ardelyx, Inc.$357
  • plus $3K from 23 others

What the payments were for

  • Food & beverage$8,29899%
  • Education$1181%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,416 in reported general payments places this provider in the 95th percentile of 8,308 physician assistant providers in Texas.

See all physician assistant providers in Texas

Medicare billing

Part B allowed, 2024
$117,383
Medicare patients
266
Services billed
4,816

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CreonLipase/Protease/Amylase13$54,117
Colestipol Hcl23$2,746
Dexlansoprazole DrDexlansoprazole13$2,522
ClenpiqSod Picosulf/Mag Ox/Citric Ac15$2,386
Peg 3350-ElectrolyteSodium Chloride/Nahco3/Kcl/Peg73$1,691
Pantoprazole Sodium77$1,493
Omeprazole70$1,277
Esomeprazole Magnesium11$473
Dicyclomine Hcl29$444
Sucralfate13$321
Ondansetron OdtOndansetron12$233

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCreon$2,877$54,11713 claims
Ferring Pharmaceuticals Inc.Clenpiq$487$2,38615 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,308 physician assistant providers in Texas.

Other physician assistant in Rockwall

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →